Cartesian Therapeutics, Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cartesian Therapeutics, Inc. (RNAC) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$32.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- Cartesian Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$7.00K, a 121.88% decline year-over-year.
- Cartesian Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $32.00K.
- Cartesian Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$5.00K.
- Cartesian Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$21.00K.
- Cartesian Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $45.00K.
- Cartesian Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$21.00K.
- Cartesian Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$53.00K, a 365.00% decline from fiscal 2022.
- Cartesian Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was $20.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$32.00K 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$7.00K 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $45.00K 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $34.00K 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $44.00K 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $32.00K 10-Q · filed 2026-04-30 | |||
| 2024-12-31 | -$21.00K 10-K · filed 2026-03-09 | |||
| 2024-09-30 | -$6.00K 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $9.00K 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$5.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$53.00K 10-K · filed 2025-03-13 | |||
| 2023-09-30 | -$69.00K 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$49.00K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$21.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $20.00K 10-K · filed 2024-03-07 | |||
| 2022-09-30 | $65.00K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $86.00K 10-Q · filed 2023-08-17 | |||
| 2022-03-31 | -$29.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$3.00K 10-K · filed 2024-03-07 | |||
| 2021-09-30 | $3.00K 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $9.00K 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$7.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$58.00K 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |